


Study	Country	AgeGrp	Sett	Pop	Samp	ROB	n	N	Proportion (%) [95% CI]
Annual									
Asthma									
Saraya, 2017*	JP	≥ 18	meda		SS AEA	0/9	3	106	2.83 [0.97, 7.99]
Charles, 2008	AU	≥ 18	meda	ED	SS PNM	1/9	7	233	3.00 [1.46, 6.07]
Ikura, 2015	JP	≥ 18	meda	IP	SS AEA	1/9	7	48	14.58 [7.25, 27.17]
Cardiopulmonary									
Gorse, 2015	US	≥ 60	comm		SS ARI	0/9	1	100	1.00 [0.18, 5.45]
Stolz, 2019	CH	>40	comm		SS ARI	0/9	16	391	4.09 [2.53, 6.54]
Seemungal, 2001	GB	≥ 18	comm		SS ARI	2/9	19	168	11.31 [7.36, 16.99]
Falsey, 2006	US	≥ 40	comm		SS ARI	0/9	11	92	11.96 [6.81, 20.15]
Charles, 2008	AU	≥ 18	meda	ED	SS PNM	1/9	10	359	2.79 [1.52, 5.05]
Snyder, 2017	US	≥ 18	meda	IP	CI AEC	3/9	7	250	2.80 [1.36, 5.67]
Kherad, 2010	CH	≥ 60	meda	IP	SS AEC	1/9	3	86	3.49 [1.19, 9.76]
Cameron, 2006	AU	>45	meda	ICU MV	SS AEC	1/9	7	107	6.54 [3.20, 12.89]
Rohde, 2003	DE	≥ 18	meda	IP	SS AEC	1/9	13	85	15.29 [9.16, 24.43]
Borg, 2003	DE	≥ 18	meda	IP	SS AEC	1/9	22	79	27.85 [19.17, 38.58]
Dimopoulos, 2015	GR	≥ 18	meda	IP	SS AEC	1/9	108	247	43.72 [37.68, 49.96]
Pancer, 2011	PL	>18	meda	OP	SS ARI	3/9	44	96	45.83 [36.22, 55.77]
REM for subgroup (Q = 285.87, p = 0.00; I ² = 95.8%)									9.68 [4.77, 18.68]
CKD									
Charles, 2008	AU	≥ 18	meda	ED	SS PNM	1/9	7	169	4.14 [2.02, 8.30]
Walker, 2014	US	≥ 18	meda	IP	CI ARI	3/9	15	96	15.62 [9.70, 24.19]
Dementia_CVD									
Charles, 2008	AU	≥ 18	meda	ED	SS PNM	1/9	4	162	2.47 [0.96, 6.18]
Diabetes									
Widmer, 2014	US	≥ 18	meda	ED/IP	SS ARI	1/9	7	302	2.32 [1.13, 4.71]
Charles, 2008	AU	≥ 18	meda	ED	SS PNM	1/9	5	159	3.14 [1.35, 7.15]
Walker, 2014	US	≥ 18	meda	IP	CI ARI	3/9	15	114	13.16 [8.14, 20.58]
Immunodeficiency									
Peghin, 2017	ES	≥ 18	comm		SS ARI	0/9	7	162	4.32 [2.11, 8.65]
Weinberg, 2010	US	≥ 18	comm		SS ARI	0/9	13	112	11.61 [6.91, 18.85]
Wansaula, 2016	US	≥ 18	meda	IP	SS SARI	2/9	0	35	0.00 [0.00, 9.89]
Sellers, 2018	US	≥ 18	meda	IP	SS ARI	1/9	1	70	1.43 [0.25, 7.66]
Theodoropoulos, 2013	US	≥ 18	meda		CI RVI	4/9	10	442	2.26 [1.23, 4.11]
Widmer, 2014	US	≥ 18	meda	ED/IP	SS ARI	1/9	19	680	2.79 [1.80, 4.32]
Jahn, 2018*	CH	≥ 18	meda		SS/CI ARI	1/9	77	2666	2.89 [2.32, 3.59]
Mahan, 2017*	US	≥ 18	meda		CI ARI	3/9	3	66	4.55 [1.56, 12.53]
Charles, 2008	AU	≥ 18	meda	ED	SS PNM	1/9	4	87	4.60 [1.80, 11.23]
Slade, 2017*	US	≥ 18	meda		SS ARI	3/9	5	104	4.81 [2.07, 10.76]
D'Angelo, 2016*	US	≥ 50	meda		SS ARI	3/9	6	118	5.08 [2.35, 10.65]
Garcia-Noblejas, 2015	ES	≥ 18	meda		CI ARI	5/9	32	570	5.61 [4.00, 7.82]
Steensels, 2019	BE	≥ 18	meda		CI ARI	3/9	31	435	7.13 [5.07, 9.94]
Walker, 2014	US	≥ 18	meda	IP	CI ARI	3/9	17	151	11.26 [7.15, 17.29]
Kumar, 2005	CA	≥ 18	meda	OP	SS RVI	1/9	6	50	12.00 [5.62, 23.80]
Teh, 2015	AU	≥ 18	meda		CI RVI	3/9	15	100	15.00 [9.31, 23.28]
Paba, 2014	IT	≥ 60	meda	IP	SS ILI	1/9	1	5	20.00 [3.62, 62.45]
Passi, 2019	IT	≥ 18	meda	IP	SS URTI	1/9	42	151	27.81 [21.29, 35.44]
REM for subgroup (Q = 200.37, p = 0.00; I ² = 88.6%)									6.33 [4.31, 9.22]
Institutionalised older adults									
Hopkins, 2008	AU	≥ 18	comm		SS ILI	0/9	18	89	20.22 [13.19, 29.72]
Widmer, 2014	US	≥ 18	meda	ED/IP	SS ARI	1/9	1	43	2.33 [0.41, 12.06]
Charles, 2008	AU	≥ 18	meda	ED	SS PNM	1/9	2	55	3.64 [1.00, 12.32]
REM for annual studies (Q = 762.02, p = 0.00; I ² = 92.1%)									7.03 [5.18, 9.48]
Seasonal									
Asthma									
Clark, 2014*	GB	≥ 18	meda	IP	SS ARI	2/9	2	171	1.17 [0.32, 4.16]
Belongia, 2018*	US	≥ 60	meda		SS ARI	2/9	33	261	12.64 [9.15, 17.22]
Cardiopulmonary									
Hutchinson, 2007	AU	≥ 18	comm		SS AEC	2/9	1	148	0.68 [0.12, 3.73]
Falsey, 2005	US	≥ 21	comm		SS ARI	2/9	56	540	10.37 [8.07, 13.23]
Ong, 2014	NL	≥ 18	meda	ICU	SS RF	3/9	1	57	1.75 [0.31, 9.29]
Loubet, 2017	FR	≥ 18	meda	IP	SS ILI	2/9	29	659	4.40 [3.08, 6.25]
Carrat, 2006	FR	≥ 18	meda	CCU	SS	2/9	6	122	4.92 [2.27, 10.32]
Reid, 2017	AU	≥ 18	meda	IP	CI AEC	4/9	11	184	5.98 [3.37, 10.39]
Puig-Barbera, 2012*	ES	≥ 60	meda	IP	SS ILI	2/9	44	639	6.89 [5.17, 9.12]
De Serres, 2009	CA	≥ 50	meda		SS AEC	2/9	8	108	7.41 [3.80, 13.94]
Camargo, 2008	US	≥ 50	meda	ED	SS AEC	2/9	6	76	7.89 [3.67, 16.17]
Falsey, 2005	US	≥ 65	meda	IP	SS ARI	2/9	142	1388	10.23 [8.74, 11.94]
Peyrani, 2012	US	≥ 18	meda	IP AEC	SS LRTI	2/9	10	48	20.83 [11.73, 34.26]
REM for subgroup (Q = 45.19, p = 0.00; I ² = 82.6%)									7.22 [5.20, 9.94]
CKD									
Loubet, 2017	FR	≥ 18	meda	IP	SS ILI	2/9	11	193	5.70 [3.21, 9.92]
Puig-Barbera, 2012*	ES	≥ 60	meda	IP	SS ILI	2/9	7	114	6.14 [3.01, 12.13]
Sundaram, 2014	US	≥ 50	meda		SS ARI	2/9	18	162	11.11 [7.14, 16.88]
Diabetes									
Loubet, 2017	FR	≥ 18	meda	IP	SS ILI	2/9	8	357	2.24 [1.14, 4.36]
Widmer, 2012	US	≥ 50	meda	IP	SS ARI	2/9	12	207	5.80 [3.35, 9.86]
Puig-Barbera, 2012*	ES	≥ 60	meda	IP	SS ILI	2/9	21	288	7.29 [4.82, 10.89]
Belongia, 2018*	US	≥ 60	meda		SS ARI	2/9	51	561	9.09 [6.98, 11.76]
Immunodeficiency									
Lopez-Medrano, 2007	ES	≥ 18	comm		SS RVI	2/9	6	152	3.95 [1.82, 8.34]
Milstone, 2006	US	≥ 18	comm		SS ARI	1/9	8	50	16.00 [8.34, 28.51]
Roghmann, 2003	US	≥ 18	comm		SS ARI	2/9	11	37	29.73 [17.49, 45.78]
Klein, 2007	CA	≥ 18	meda	OP	SS ARI	3/9	0	50	0.00 [0.00, 7.13]
Loubet, 2017	FR	≥ 18	meda	IP	SS ILI	2/9	15	220	6.82 [4.18, 10.94]
Widmer, 2012	US	≥ 50	meda	IP	SS ARI	2/9	19	241	7.88 [5.11, 11.98]
Belongia, 2018*	US	≥ 60	meda		SS ARI	2/9	15	182	8.24 [5.06, 13.15]
Mikulsa, 2014	IT	≥ 18	meda	OP	SS ARI	1/9	18	193	9.33 [5.98, 14.26]
Ong, 2014	NL	≥ 18	meda	ICU	SS RF	3/9	3	32	9.38 [3.24, 24.22]
Leibl, 2017	CH	≥ 18	meda		SS ARI	2/9	11	100	11.00 [6.25, 18.63]
Puig-Barbera, 2012*	ES	≥ 60	meda	IP	SS ILI	2/9	2	16	12.50 [3.50, 36.02]
Sanghavi, 2012	US	≥ 18	meda		CI ARI	5/9	17	105	16.19 [10.36, 24.41]
Gueller, 2013*	DE	≥ 18	meda	IP	SS	4/9	10	29	34.48 [19.94, 52.65]
REM for subgroup (Q = 47.98, p = 0.00; I ² = 78.1%)									11.28 [7.75, 16.13]
Institutionalised older adults									
Diaz-Decaro, 2016*	US	≥ 18	comm		SS ARI	1/9	1	52	1.92 [0.34, 10.12]
Chasqueira, 2018	PT	≥ 59	comm		SS ARI	1/9	5	188	2.66 [1.14, 6.07]
Johnstone, 2014	CA	≥ 65	comm		SS ARI	2/9	12	269	4.46 [2.57, 7.63]
Hequet, 2019	CH	≥ 18	comm		SS ILI	1/9	38	509	7.47 [5.49, 10.08]
Widmer, 2012	US	≥ 50	meda	IP	SS ARI	2/9	4	46	8.70 [3.43, 20.32]
REM for subgroup (Q = 8.49, p = 0.08; I ² = 52.4%)									5.20 [3.27, 8.17]
REM for seasonal data (Q = 154.30, p = 0.00; I ² = 84.5%)									7.69 [6.23, 9.46]



RSV proportion